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Abstract
We evaluated microcalorimetry for real-time susceptibility testing
of Aspergillus spp. based on growth-related heat production. The
minimal heat inhibitory concentration (MHIC) for A. fumigatus
ATCC 204305 was 1 mg/L for amphotericin B, 0.25 mg/L for
voriconazole, 0.06 mg/L for posaconazole, 0.125 mg/L for caspo-
fungin and 0.03 mg/L for anidulafungin. Agreement within two 2-
fold dilutions between MHIC (determined by microcalorimetry)
and MIC or MEC (determined by CLSI M38A) was 90% for
amphotericin B, 100% for voriconazole, 90% for posaconazole
and 70% for caspofungin. This proof-of-concept study demon-
strated the potential of isothermal microcalorimetry for growth
evaluation of Aspergillus spp. and real-time antifungal susceptibility
testing.
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The prevalence of less susceptible Aspergillus strains is contin-
uously rising, including non-fumigatus species [1], highlighting
the need for antifungal susceptibility testing. Conditions for
susceptibility testing of moulds by microbroth dilution have
been defined by the CLSI [2] and the Antifungal Susceptibility
Testing Subcommittee of EUCAST [3]. Broth-dilution assays
are labour-intensive, variably reproducible and require expe-
rienced personnel. Sensititre Yeast One is a colorimetric
microdilution method adapted from the susceptibility testing
of yeast by the CLSI guidelines [4]. While Sensititre Yeast
One showed good correlation with standard susceptibility of
moulds for amphotericin B and triazoles, further evaluation
is needed for echinocandins [5,6].
The principle of microcalorimetry relies on the measure
of microbial heat production based on their growth and
metabolism [7]. Recently, the potential of isothermal micro-
calorimetry was studied in the microbiology setting, including
the differentiation between methicillin-susceptible and methi-
cillin-resistant Staphylococcus aureus within 5 h [8], the sus-
ceptibility testing of Escherichia coli and S. aureus [9] and the
evaluation of drugs against Schistosoma mansoni [10]. In this
study, we investigated the potential of microcalorimetry for
antifungal susceptibility testing of medically important Asper-
gillus species, including defined resistant mutants.
Ten Aspergillus strains were investigated (Table 1). They
were subcultured on Sabouraud dextrose agar and identified
on the basis of macroscopic and microscopic morphological
features. Amphotericin B (Sigma, St Louis, MO, USA), vorico-
nazole and posaconazole (TRC, North York, ON, Canada),
caspofungin (Merck & Co., Inc., Whitehouse Station, NJ, USA)
and anidulafungin (Pfizer Pharma AG, Zu¨rich, Switzerland)
were tested. Microbroth dilution was performed as described
in the CLSI document M38-A2 [2]. The minimal effective con-
centration (MEC) was determined only for caspofungin,
defined as the lowest drug concentration at which short and
branched hyphae were observed [11]. Antifungal susceptibility
testing was additionally performed with the commercial Sensi-
titre YeastOne panel (Trek Diagnostic System Ltd, East Grin-
stead, UK) according to the manufacturer’s instructions.
Colorimetric MEC was defined as the lowest concentration
visibly reducing growth (despite presence of red or purple
colour). We added the colorimetric Sensititre YeastOne assay
for comparison of susceptibility testing because several rou-
tine microbiology laboratories are using this method rather
than the CLSI-reference microbroth dilution.
For microcalorimetric evaluation of growth characteristics,
Sabouraud dextrose broth (SDB) (Oxoid CM0147; Basing-
stoke, Hampshire, UK) was used (3 mL medium and 1 mL
air in the headspace of the ampoule). An inoculum of c.
2.5 · 104 conidia/mL was used, determined by microscopic
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enumeration using a Neubauer haematocytometer. Air-tightly
sealed ampoules were introduced into the isothermal micro-
calorimeter (TAM III; TA Instruments, Newcastle, DE, USA)
and measurements were performed at 37C every 10 s. The
detection threshold was determined at 5 lW to distinguish
fungal heat production from the thermal background noise
(i.e. growth media without moulds). The detection time (in
h), heat-flow peak (in lW), the time to peak (h) and total
heat produced (in Joules, represented by the area under the
heat-flow curve) at 24, 48 and 72 h were determined. For
testing antifungal agents, two-fold dilutions of antifungal
agents were added to SDB. The minimal heat inhibitory con-
centration (MHIC) of amphotericin B and triazoles was
defined as the lowest antifungal concentration inhibiting 50%
of the total heat produced by the growth control at 48 h.
For echinocandins, the MHIC was defined as the lowest con-
centration reducing the heat-flow peak by 50%. Susceptibility
testing experiments were performed in duplicate. Data analy-
sis was carried out with the manufacturer’s software (TAM
Assistant; TA Instruments) and GraphPad Prism 5.0 (Graph-
Pad Software, La Jolla, CA, USA).
The thermokinetic characteristics of the Aspergillus strains
tested in the absence of antifungals are presented in Table S1.
The median heat detection time was <5 h, except for A. fumiga-
tus CM-2097 and A. niger, which required 14 and 7.7 h, respec-
tively. The total heat produced ranged between 4.4–8.3 J after
48 h and 4.7–10 J after 72 h. The median time to reach the
heat-flow peak was 22 h. The heat production stopped com-
pletely after the peak was reached (i.e. the heat-flow curve
returned to baseline), except for A. flavus and A. oryzae, which
continuously produced heat of c. 20 lW up to 72 h. Among
different growth media tested (data not shown), SDB showed a
larger heat production (and shorter detection time) than RPMI
1640. Therefore, SDB was used in subsequent antifungal sus-
ceptibility experiments. Similar observations using growth
curves were reported by Meletiadis et al. [12].
Table 1 summarizes the MHIC values obtained by microcal-
orimetry, and the MIC and MEC values obtained by the CLSI
microbroth dilution and by Sensititre YeastOne. Fig. 1 shows
the effect of antifungals tested on the heat production of A. fu-
migatus ATCC 204305. Amphotericin B (Fig. 1a) delayed the
heat production in a concentration-dependent manner with-
out significant change of the heat-flow curve profile, indicating
its fungicidal activity. A similar killing effect of bactericidal anti-
biotics was previously described for bacteria [13]. Voriconaz-
ole and posaconazole (Fig. 1b,c) showed a fungistatic effect at
low concentrations, reflected by a reduced initial heat-flow
slope, but delayed the fungal heat production at higher con-
centrations (fungicidal activity). A similar fungistatic effect of
various alcohols was previously reported on yeasts [14].T
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FIG. 1. Determination of the minimal heat
inhibitory concentration (MHIC) by microcal-
orimetry for A. fumigatus ATCC 204305. Heat
flow (left panel) and total heat (right panel) of
A. fumigatus in the presence of amphotericin B
(a), voriconazole (b), posaconazole (c), caspo-
fungin (d) and anidulafungin (e) in SDB med-
ium using an inoculum of 2.5 · 104 conidia/
mL. Numbers indicate the antifungal concen-
tration (in mg/L); GC denotes growth control
without antifungals. The dotted horizontal line
indicates 50% of inhibition of total heat pro-
duced by the growth control after 48 h (for
amphotericin B and triazoles) or a 50%
decrease in the heat-flow peak (for echinocan-
dins). The MHIC value is circled.
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Triazoles in addition decreased the heat-flow peak, whereas
this effect was not observed with amphotericin B. While echi-
nocandins are fungicidal against Candida species, they are only
fungistatic against Aspergillus species [15]. This difference was
also observed by microcalorimetry, where caspofungin and
anidulafungin (Fig. 1d,e) changed the initial slope of the heat-
flow and lowered the peak, but were not able to completely
inhibit heat production. This effect could be explained by the
interference of antifungals in Aspergillus metabolic activity, chang-
ing their growth mode from filamentous to granular. With the
conventional susceptibility method, the change of growth mode
is determined by visual inspection; the determination of MEC
requires experienced personnel and the interpretation can be
subjective. A concentration-dependent activity of echinocandins
on Aspergillus spp. was observed by microcalorimetry, which is
in agreement with other reports [16]. In order to systematically
evaluate the antifungal activity on non-fumigatus Aspergillus spe-
cies, one drug from each antifungal class was investigated on
each test strain (Figs S1–S6).
We challenged the microcalorimetry susceptibility assay by
testing azole-resistant mutants of A. fumigatus [17,18] (Table 1
and Fig. S7). While no breakpoints have been determined for
triazoles, an epidemiological cut-off value for posaconazole in
A. fumigatus was determined at 0.25 mg/L and a resistance
breakpoint of >0.5 mg/L was proposed [19]. Using this break-
point value, all three methods were able to detect resistance,
although variability in MIC/MHIC values was observed.
The percentage of agreement (within two 2-fold dilutions)
between the MHIC and MIC (or MEC) by CLSI was 90%,
100%, 90% and 70% for amphotericin B, voriconazole, posa-
conazole and caspofungin, respectively. Of note, the Sensititre
YeastOne assay has not been fully evaluated for echinocan-
dins and the interpretation of MEC by this colorimetric
method is challenging. For anidulafungin, lower MEC values
against Aspergillus species were reported than for caspofungin
[20], as was observed also in our microcalorimetry assay.
In summary, this proof-of-concept study demonstrated the
potential of isothermal microcalorimetry for growth evalua-
tion of Aspergillus spp. and the determination of its antifungal
susceptibility in real time. This method might be used for
testing new antifungal agents, including investigation of their
mode-of-action, growth-phase specific activity and interac-
tions between antifungals.
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Figure S1. Heat flow (left panel) and total heat (right
panel) of Aspergillus terreus in the presence of amphotericin B
(a), voriconazole (b) and anidulafungin (c) in SDB medium
using an inoculum of c. 104 conidia/mL.
Figure S2. Heat flow (left panel) and total heat (right
panel) of Aspergillus flavus in the presence of amphotericin B
(a), voriconazole (b) and caspofungin (c).
Figure S3. Heat flow (left panel) and total heat (right
panel) of Aspergillus niger in the presence of amphotericin B
(a), posaconazole (b) and caspofungin (c).
Figure S4. Heat flow (left panel) and total heat (right
panel) of Aspergillus oryzae in the presence of amphotericin B
(a), posaconazole (b) and anidulafungin (c).
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Figure S5. Heat flow (left panel) and total heat (right
panel) of Aspergillus lentulus in the presence of amphotericin
B (a), voriconazole (b) and anidulafungin (c).
Figure S6. Heat flow (left panel) and total heat (right
panel) of Aspergillus nidulans in the presence of amphotericin
B (a), posaconazole (b) and caspofungin (c).
Figure S7. Heat flow (left panel) and total heat (right
panel) of Aspergillus fumigatus CM-237 (wild type) MIC 0.06
(a), CM-796 (Dcyp51a/b) MIC 16 (b) and CM-2097
(Dcyp51a) MIC 16 (c) in the presence of posaconazole.
Table S1. Calorimetric characteristics of Aspergillus spe-
cies in SDB at 37C. The inoculum was c. 104 conidia/mL.
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials supplied
by the authors. Any queries (other than missing material)
should be directed to the corresponding author for the arti-
cle.
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